帕博西尼通过抑制ATM激酶介导的DNA损伤反应增强肝癌和胆管癌的放射敏感性
帕博西尼是口服CDK4/6抑制剂,在乳腺癌治疗中有效。本研究评估帕博西尼联合放疗对肝细胞癌和胆管癌的抗癌效果及分子机制。结果显示帕博西尼通过PP5介导抑制ATM激酶,影响DNA双链断裂修复,增强放射敏感性,体内外实验均证实协同作用。
要点
- 帕博西尼增强肝细胞癌和胆管癌细胞的放射敏感性。
- 机制涉及抑制ATM激酶介导的DNA损伤反应,由PP5介导。
- 临床前模型支持帕博西尼作为放疗辅助的临床试验。
核心结论
- 帕博西尼通过抑制PP5-ATM轴增强肝细胞癌和胆管癌的放射敏感性,提供新的联合治疗策略。
研究设计与样本
- 临床前研究,包括体外细胞实验和体内肝细胞癌异种移植模型。
主要发现
- 帕博西尼影响DNA修复动力学,增强放射诱导的细胞毒性。
- 帕博西尼抑制ATM激酶,其作用由蛋白磷酸酶5(PP5)介导。
- 体内外研究显示帕博西尼与放疗协同,归因于DNA损伤后PP5-ATM轴的抑制。
临床怎么用
- 帕博西尼可作为放疗辅助用于肝细胞癌和胆管癌,需进一步临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Palbociclib is an oral cyclin-dependent kinase 4/6 inhibitor, which is efficacious in treating breast cancer. Currently, there are numerous active clinical trials testing palbociclib alone or in combination with other medications for treating various types of malignancies. Here, we evaluated the anti-cancer effect of palbociclib in combination with radiation therapy (RT) for treating human hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) and addressed the molecular mechanism behind the combination therapy. METHODS: Immunofluorescence staining of γH2AX or 53BP1 was used to determine the effect of palbociclib on double-strand break (DSB) repair. Clonogenic assays, sphere formation and cell death ELISA were performed to study the sensitising effect of palbociclib on radiation-induced cytotoxicity. Signal alteration in DSB repair pathways was examined by Western blot analysis. Finally, we evaluated the in vivo anti-cancer activity and the associated molecular events of the combination therapy in a preclinical HCC xenograft model. RESULTS: Palbociclib affected the kinetics of DNA repair and enhanced the radiation sensitivity of HCC and CCA cells. Importantly, we found that palbociclib inhibits ataxia telangiectasia-mutated (ATM) kinase, the key upstream kinase responding to RT-induced DSBs. Furthermore, we showed that the inhibitory effect of palbociclib on RT-induced ATM kinase activation is mediated by protein phosphatase 5 (PP5). Both in vitro and in vivo investigations revealed that the inhibition of the PP5-ATM axis by palbociclib after DNA damage is responsible for the synergism between palbociclib and RT. CONCLUSION: Our findings provide a novel combination strategy against liver cancer cells. Clinical trials using palbociclib as an adjuvant in RT are warranted.
引用
- Huang CY, Hsieh FS, Wang CY, et al. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response. Eur J Cancer. 2018. PMID: 30103095. doi:10.1016/j.ejca.2018.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。